Roche

AC Immune, Genentech form second antibody collaboration for Alzheimer's

Monday, June 18, 2012 03:03 PM

Swiss-based biopharmaceutical company AC Immune has entered into a second exclusive worldwide license agreement and research collaboration with Genentech, a member of the Roche Group, for research, development and commercialization of AC Immune's anti-Tau antibodies for the potential treatment of Alzheimer's disease and other neurodegenerative diseases.

More... »

FDA approves Perjeta for HER2-positive metastatic breast cancer

Monday, June 11, 2012 03:03 PM

The FDA has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

More... »

Roche forms alliance with med fusion

Wednesday, June 6, 2012 12:45 PM

Roche has formed a strategic alliance with med fusion of Lewisville, Texas, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.

More... »

SoftGenetics, 454 Life Sciences promote next-gen sequencing software

Monday, May 14, 2012 01:19 PM

SoftGenetics and 454 Life Sciences, a Roche subsidiary, have entered into a co-promotion agreement designed to provide users of 454 Sequencing Systems with the sequencing data analysis options provided by SoftGenetics’ NextGENe software.

More... »

Roche will not extend offer for Illumina

Wednesday, April 18, 2012 11:00 AM

Roche has decided not to extend its tender offer for Illumina, based on preliminary estimates indicating the re-election of the incumbent directors of Illumina. Roche’s cash tender offer is due to expire on April 20, 2012 at 6 p.m. EST.

More... »

Seattle Genetics, Millennium, Ventana collaborate on companion diagnostic test for Adcetris

Friday, April 13, 2012 12:37 PM

Seattle Genetics and Millennium, a subsidiary of Takeda Pharmaceutical, have formed a collaboration with Ventana Medical Systems, a member of the Roche Group, through which Ventana will seek to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with Adcetris based on CD30 expression levels in their tissue specimens.

More... »

Roche disappointed with ISS recommendation

Monday, April 9, 2012 09:19 AM

The Institutional Shareholder Services (ISS) has recommended that shareholders of Illumina vote against the election of Roche’s independent director nominees to Illumina’s board of directors.

More... »

Burrill wraps up life sciences industry for Q1 2012

Wednesday, April 4, 2012 03:00 PM

Burrill & Company, a diversified global financial services firm focused on the life sciences industry, has identified more than $2.6 billion in expected funding through nine translational research and early-stage initiatives announced since the end of February.

More... »

Daiichi forms diabetes alliance with NGM Biopharma

Friday, March 30, 2012 03:07 PM

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

More... »

Roche increases offer for Illumina $51 per share

Friday, March 30, 2012 09:17 AM

Roche has increased its offer price for all outstanding publicly-held shares of Illumina, $51 per share in cash. All other terms and conditions of the tender offer remain unchanged.

More... »